The article "Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential" by Min Sun et al. explores the potential of sodium-glucose cotransporter 2 (SGLT-2) inhibitors as anticancer agents. SGLT-2 inhibitors, commonly used to treat diabetes, have shown promising anticancer properties in various cancer types, including hepatocellular, pancreatic, prostate, colon, lung, and breast carcinomas. The authors highlight the mechanisms by which SGLT-2 inhibitors exert their anticancer effects, such as reducing glucose uptake by cancer cells, systemic glucose restriction, cell cycle arrest, and regulation of signaling pathways. They also discuss the metabolic enzymes involved in the metabolism of different SGLT-2i species and their impact on cancer cell growth and survival. The article reviews clinical studies and preclinical experiments that support the anticancer efficacy of SGLT-2i, emphasizing their potential as adjunct therapies in conventional cancer treatments. The authors conclude by highlighting the need for further research to optimize the use of SGLT-2i in cancer therapy.The article "Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential" by Min Sun et al. explores the potential of sodium-glucose cotransporter 2 (SGLT-2) inhibitors as anticancer agents. SGLT-2 inhibitors, commonly used to treat diabetes, have shown promising anticancer properties in various cancer types, including hepatocellular, pancreatic, prostate, colon, lung, and breast carcinomas. The authors highlight the mechanisms by which SGLT-2 inhibitors exert their anticancer effects, such as reducing glucose uptake by cancer cells, systemic glucose restriction, cell cycle arrest, and regulation of signaling pathways. They also discuss the metabolic enzymes involved in the metabolism of different SGLT-2i species and their impact on cancer cell growth and survival. The article reviews clinical studies and preclinical experiments that support the anticancer efficacy of SGLT-2i, emphasizing their potential as adjunct therapies in conventional cancer treatments. The authors conclude by highlighting the need for further research to optimize the use of SGLT-2i in cancer therapy.